Although tissue- and liquid-biopsy based testing for the purpose of predicting NE/SC is still at the exploratory stage, it is a promising area of research and development that will enable early detection and precision therapy for a lethal form of prostate cancer trending to rise in frequency due to early use of potent AR-targeting agents. The gene discussed is AR; the disease is Familial prostate cancer.